Next-generation, oral selective oestrogen receptor degraders (SERDs) have been shown to improve outcomes in patients with advanced-stage oestrogen receptor (ER)-positive, HER2-negative breast cancer, particularly those with acquired ESR1 mutations. Now, the proteolysis-targeting chimera (PROTAC) SERD vepdegestrant, which induces ER degradation directly rather than indirectly, has also demonstrated efficacy in this setting, raising questions over the optimal choice and sequencing of treatments.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McDonnell, D. P., Wardell, S. E., Chang, C. & Norris, J. Next-generation endocrine therapies for breast cancer. J. Clin. Oncol. 39, 1383–1388 (2021).
Turner, N. C. et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clin. Cancer Res. 26, 5172–5177 (2020).
Bidard, F. C. et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J. Clin. Oncol. 40, 3246–3256 (2022).
Oliveira, M. et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 25, 1424–1439 (2024).
Jhaveri, K. L. et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N. Engl. J. Med. 392, 1189–1202 (2025).
Gheysen, M., Punie, K., Wildiers, H. & Neven, P. Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review. Cancer Treat. Rev. 130, 102825 (2024).
Campone, M. et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2505725 (2025).
Cardoso, F. et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 76, 103756 (2024).
Bardia, A. et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR-1 mutated tumours: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK 4/6 inhibitor and in clinical subgroups. Clin. Cancer Res. 30, 4299–4309 (2024).
Bardia, A. et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK 4/6 inhibitors (TRINITI-1). Clin. Cancer Res. 27, 4177–4185 (2021).
Acknowledgements
The authors thank N. Willers for their assistance in generating the Supplementary Figure for this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Neven, P., Han, S.N. PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations. Nat Rev Clin Oncol 22, 709–710 (2025). https://doi.org/10.1038/s41571-025-01062-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-025-01062-6
